# US 10,369,202 B2 · Treatment of mammalian physiological reaction of IgE antibodies present in said mammal upon contact with the corresponding antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,369,202 B2
- Document ID: US10369202B2
- Status: Granted
- Kind: B2
- Application number: 15/942,767
- Filed: 2018-04-02
- Published: 2018-08-09
- Granted: 2019-08-06
- Earliest claimed: 2002-11-21
- Applicants: Ira Sanders
- Inventors: Ira Sanders
- Web page: https://patentgrep.com/patent/US10369202B2

## CPC

- A61K 38/4893: {Botulinum neurotoxin (3.4.24.69)}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0031: {Rectum, anus}
- A61K 9/0043: {Nose}
- A61K 9/0046: {Ear}
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- A61K 9/0073: {Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy; (nasal sprays A61K9/0043; inhalation of vapours of volatile or heated drugs, e.g. essential oils or nicotine, A61K9/007; devices A61M)}
- A61K 38/164: {from bacteria}
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 11/08: Bronchodilators
- A61P 11/12: Mucolytics
- A61P 11/14: Antitussive agents
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- C12N 15/74: Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K 2039/543: {intranasal}
- C12Y 304/24069: Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

A method is disclosed for blocking or reducing a physiological reaction in a mammal to the interaction of IgE antibodies present in said mammal upon contact with the corresponding antigen, by the administration to said mammal of a therapeutically effective amount of a neurotoxin (CnT) derived from Clostridia sp.

## Claims

### Claim 1

A method of treating an allergic condition or a symptom thereof in a patient in need thereof, comprising administering an effective amount of a neurotoxin (CnT) to a body structure involved in said allergic condition and/or a nerve and nerve ganglia supplying the body structure of the patient, wherein the CnT is isolated or purified from a species of Clostridia selected from the group consisting of C. botulinum, C. burtyricum and C. beratti, and wherein the allergic condition is selected from the group consisting of allergic rhinitis, allergic asthma, allergic gastroenteritis, allergic serous otitis media, allergic sinusitis, and allergic dermatitis.

### Claim 2 (depends on 1)

The method of claim 1, wherein the allergic condition is allergic gastroenteritis.

### Claim 3 (depends on 2)

The method of claim 2, wherein the administering is to the gastrointestinal tract of the patient.

### Claim 4 (depends on 1)

The method of claim 1, wherein the administering is by injection.

### Claim 5 (depends on 1)

The method of claim 1 wherein the amount of CnT administered is between about 0.1 and about 1,000 units.

### Claim 6 (depends on 1)

The method of claim 1 wherein the amount of CnT administered is between about 1 and about 100 units.

### Claim 7 (depends on 1)

The method of claim 1, wherein the amount of CnT administered is between about 1 and about 20 units.

### Claim 8 (depends on 1)

The method of claim 1, wherein the CnT is a fragment, altered form, or recombinant form of CnT.

### Claim 9 (depends on 1)

The method of claim 1, wherein the CnT is administered topically.